Pfizer chips in on $26M raise for rheumatoid arthritis collaborator; Hansoh licenses an anti-fungal for a mysterious infection
Two weeks after Pfizer jumped into an R&D partnership with Imcyse, the Belgian biotech reports that the pharma giant has helped contribute to a new, $26 million add-on raise to their B round.
Imcyse reports Wednesday morning that the added cash will go to help fund its work on a pipeline of immunotherapies. Biogenosis, Epimede, LSP, Noshaq, Société Régionale d’Investissement de Wallonie (SRIW), Société Fédérale de Participations et d’Investissement (SFPI) and KU Leuven all participated.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.